Rachel Gray

Learn More
The BCR/ABL tyrosine kinase inhibitor imatinib mesylate (Gleevec, STI571; No-vartis, Basel, Switzerland) has shown remarkable efficacy in the treatment of chronic myelogenous leukemia (CML), with a high proportion of patients achieving complete cytogenetic responses (CCRs). However, it is not clear whether remissions will be durable and whether imatinib(More)
UNLABELLED A previously fit and well 57-year-old gentleman who had recently undergone a colonoscopy and biopsy of a polyp presented with a 4-day history of progressive breathlessness and abdominal discomfort. The day after admission, he became haemodynamically unstable, developed ischaemic legs and suffered a brief cardiac arrest. Blood tests demonstrated a(More)
BACKGROUND Type 2 diabetes mellitus (T2DM) is a major global health problem. An estimated 20%-50% of diabetic subjects in Canada are currently undiagnosed, and around 20%-30% have already developed complications. Screening for high blood glucose levels can identify people with prediabetic conditions and permit introduction of timely and effective(More)
  • 1